Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Contract Manufacturing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • Suppliers
    • The Big 100
      • Archive – The Big 100 (2018)
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • Leadership
    • Women in Medtech
    • 2020 Winners
    • 2019 Winners

Spark Biomedical wins FDA breakthrough nod for newborn opioid withdrawal relief device

December 16, 2020 By Nancy Crotti

The Roo system (Image courtesy of Spark Biomedical)

Spark Biomedical announced today that the FDA granted breakthrough device designation to its transcutaneous electrical nerve stimulator designed to reduce signs and symptoms of neonatal opioid withdrawal syndrome (NOWS).

NOWS results from exposure to prescription or non-prescription opioids such as methadone or heroin during pregnancy. Currently, no nationwide standard of care exists for managing NOWS, although oral morphine weaning for a national average of 21 days is common practice.

The Roo system is a non-invasive neurostimulation device based on the company’s adult device, the Sparrow therapy system. Intended to be applied by healthcare professionals in a neonatal intensive care unit, the system is designed to promote the release of endogenous opioids (endorphins), supplanting the need for oral morphine. The endorphin release is achieved by safely activating nerve branches on and around the ear of newborn infants, according to the Dallas, Texas-based company.

In tandem with its FDA breakthrough submission, Spark began an NIH/NIDA-funded clinical study with the Medical University of South Carolina to assess the safety and effectiveness of the Roo System in neonates as an adjunctive therapy to the use of oral morphine. The data from this clinical study, used to support the FDA’s breakthrough decision, demonstrated that the Roo System can significantly reduce the duration of oral morphine use to less than ten days with no adverse events, according to the company.

“We know that an increase in opioid misuse can have a direct connection to a rise in NOWS cases,” said Spark Biomedical CEO Daniel Powell in a news release. “We submitted the Roo system for breakthrough device designation because we see a growing need and we’re dedicated to getting this solution to the most vulnerable of patients as quickly as possible.”

“It is heartbreaking to see babies go through withdrawal,” added Spark’s chief technology officer, Alejandro Covalin. “It is a privilege to have this opportunity to develop technology to help these babies overcome NOWS and minimize the potentially lifelong consequences of current treatments. Breakthrough device designation is evidence of the need for this therapy and will help us expedite the delivery of a life-changing technology to those in dire need.”

Related Articles Read More >

Medical device companies put $3.6 billion in docs’ pockets, study finds
Smisson-Cartledge Biomedical
FDA slaps Class I label on rapid infuser recall
Resonetics to expand manufacturing in Costa Rica
Viant
Viant expands factory in Costa Rica

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Tweets by MedTechDaily

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Medical Tubing + Extrusion
  • MedTech 100
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertising
  • Subscribe to Enewsletter
  • Subscribe to Print Magazine
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our Device Talks Tuesdays Discussion

Copyright © 2021 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Contract Manufacturing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • Suppliers
    • The Big 100
      • Archive – The Big 100 (2018)
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • Leadership
    • Women in Medtech
    • 2020 Winners
    • 2019 Winners